{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:14:46Z","timestamp":1793942086956,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and Aim<\/jats:title>\n                <jats:p>Maintenance haemodialysis patients have increased morbidity and mortality which is mainly driven by an elevated inflammation level due to the uraemic milieu. A major part of this increased inflammation level is the degree of oxidative stress which can be assessed by albumin redox state (ARS). Aim of this study was to evaluate how the ARS is affected by a haemodialysis treatment and different dialyzer properties.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ARS was determined before and after haemodialysis treatment by fractionating it into reduced human mercaptalbumin (HMA), reversibly oxidized human non-mercaptalbumin 1 (HNA-1), and irreversibly oxidized human non-mercaptalbumin 2 (HNA-2) by high-performance liquid chromatography. In healthy individuals, albumin circulates in the following proportions: HMA 70\u201380%, HNA-1 20\u201330% and HNA-2 2\u20135%. High flux (FX 100 [Fresenius Medical Care], BG 1.8 [Toray], Xevonta Hi 18 [B. Braun], CTA-2000 [Kawasumi]) and low flux FX10 [Fresenius Medical Care] dialyzers were used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>58 patients (59% male, median age 68 years, median time on haemodialysis 32 month) were included in the study. Before haemodialysis treatment, HMA (median 55.9%, IQR 50.1\u201361.2%) was substantially lower than in healthy individuals. Accordingly, oxidized albumin fractions were above the level of healthy individuals (median HNA-1 38.5%, IQR 33.3\u201343.2%; median HNA-2 5.8%, IQR 5.1\u20136.7%). Before haemodialysis treatment HMA was significantly higher in patients usually treated with high flux membranes (p\u2009&lt;\u20090.01). After haemodialysis treatment there was a significant increase of HMA and a decrease of HNA-1 and HNA-2 (p\u2009&lt;\u20090.01). These effects were more pronounced in patients treated with high flux dialyzers (p\u2009&lt;\u20090.01). There were no differences of ARS alteration with regard to the dialyzer\u00b4s sterilization mode or the presence of diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study confirms that the ARS is positively altered by haemodialysis and shows for the first time that this effect depends on dialyzer properties.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03317-9","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T10:01:57Z","timestamp":1695031317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Albumin redox state of maintenance haemodialysis patients is positively altered after treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Kristina","family":"Boss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margret","family":"Paar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Waterstradt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Schnurr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ickerott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Wieneke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Spitth\u00f6ver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Oettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"issue":"5","key":"3317_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048\u201350.","journal-title":"Kidney Int"},{"key":"3317_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41581-022-00542-7","volume":"18","author":"AK Bello","year":"2022","unstructured":"Bello AK, Okpechi IG, Osman MA, et al. Epidemiology of haemodialysis outcomes. Nat Rev Nephrol. 2022;18:378\u201395.","journal-title":"Nat Rev Nephrol"},{"key":"3317_CR3","unstructured":"United States Renal DCTA System (USRDS). Chapter 5: Mortality. https:\/\/www.usrds.org\/2018\/view\/v2_05.aspx. (20 september 2019, date last accessed)."},{"key":"3317_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ckj\/sfx149","volume":"11","author":"A Kramer","year":"2018","unstructured":"Kramer A, Pippias M, Noordzij M, et al. The european Renal Association \u2013 European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. Clin Kidney J. 2018;11:108\u201322.","journal-title":"Clin Kidney J"},{"issue":"suppl3","key":"3317_CR5","doi-asserted-by":"publisher","first-page":"iii35","DOI":"10.1093\/ndt\/gfy175","volume":"33","author":"G Cobo","year":"2018","unstructured":"Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33(suppl3):iii35\u2013iii40.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"3317_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00467-018-4005-4","volume":"34","author":"K Daenen","year":"2019","unstructured":"Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. Pediatr Nephrol. 2019;34(6):975\u201391.","journal-title":"Pediatr Nephrol"},{"issue":"13","key":"3317_CR7","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.febslet.2008.04.057","volume":"582","author":"M Roche","year":"2008","unstructured":"Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582(13):1783\u20137.","journal-title":"FEBS Lett"},{"key":"3317_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0076-6879(10)74011-8","volume":"474","author":"K Oettl","year":"2010","unstructured":"Oettl K, Marsche G. Redox state of human serum albumin in terms of cysteine-34 in health and disease. Methods Enzymol. 2010;474:181\u201395.","journal-title":"Methods Enzymol"},{"issue":"5","key":"3317_CR9","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.xphs.2022.03.005","volume":"111","author":"A Farrugia","year":"2022","unstructured":"Farrugia A, Mori F. Therapeutic solutions of human albumin\u2014the possible effect of process-induced molecular alterations on clinical efficacy and safety. J Pharm Sci. 2022;111(5):1292\u2013308.","journal-title":"J Pharm Sci"},{"issue":"7","key":"3317_CR10","doi-asserted-by":"publisher","first-page":"e70822","DOI":"10.1371\/journal.pone.0070822","volume":"8","author":"PS Lim","year":"2013","unstructured":"Lim PS, Jeng Y, Wu MY, Pai MA, Wu TK, Liu CS, Chen CH, Kuo YC, Chien SW, Chen HP. Serum oxidized albumin and cardiovascular mortality in normoalbuminemic hemodialysis patients: a cohort study. PLoS ONE. 2013;8(7):e70822.","journal-title":"PLoS ONE"},{"key":"3317_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/ki.1985.136","volume":"28","author":"AT Nguyen","year":"1985","unstructured":"Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo within micro amounts of whole blood. Kidney Int. 1985;28:58\u2013167.","journal-title":"Kidney Int"},{"issue":"3","key":"3317_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0925-4439(03)00093-0","volume":"1638","author":"B Mayer","year":"2003","unstructured":"Mayer B, Zitta S, Greilberger J, Holzer H, Reibnegger G, Hermetter A, Oettl K. Effect of hemodialysis on the antioxidative properties of serum. Biochim Biophys Acta. 2003;1638(3):267\u201372.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"3317_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40620-017-0441-7","volume":"30","author":"B Di Iorio","year":"2017","unstructured":"Di Iorio B, Di Micco L, Bruzzese D, Nardone L, Russo L, Formisano P, D\u2019Esposito V, Russo D. Erratum to: Ultrapure dialysis water obtained with additional ultrafilter may reduce inflammation in patients on hemodialysis. J Nephrol. 2017;30(6):883.","journal-title":"J Nephrol"},{"issue":"1","key":"3317_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10047-018-1059-9","volume":"22","author":"M Kohlov\u00e1","year":"2019","unstructured":"Kohlov\u00e1 M, Amorim CG, Ara\u00fajo A, Santos-Silva A, Solich P, Montenegro MCBSM. The biocompatibility and bioactivity of hemodialysis membranes: their impact in end-stage renal disease. J Artif Organs. 2019;22(1):14\u201328.","journal-title":"J Artif Organs"},{"key":"3317_CR15","unstructured":"Deutsche Gesellschaft f\u00fcr Nephrologie. Dialysestandard. https:\/\/www.dgfn.eu\/dialyse-standard.html. Accessed 05.01.2023."},{"key":"3317_CR16","doi-asserted-by":"crossref","unstructured":"Schneditz D, Putz-Bankuti C, Ribitsch W, Schilcher G. Correction of plasma concentrations for effects of hemoconcentration or hemodilution. ASAIO J. 2012 Mar-Apr;58(2):160\u20132.","DOI":"10.1097\/MAT.0b013e318243660f"},{"issue":"6","key":"3317_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/ndt\/gfx191","volume":"33","author":"MK van Gelder","year":"2018","unstructured":"van Gelder MK, Abrahams AC, Joles JA, Kaysen GA, Gerritsen KGF. Albumin handling in different hemodialysis modalities. Nephrol Dial Transplant. 2018;33(6):906\u201313.","journal-title":"Nephrol Dial Transplant"},{"key":"3317_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/IJNRD.S291348","volume":"14","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Ficociello LH, Bazzanella J, Mullon C, Anger MS. Slipping through the pores: hypoalbuminemia and albumin loss during Hemodialysis. Int J Nephrol Renovasc Dis. 2021;14:11\u201321.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"6","key":"3317_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1159\/000082524","volume":"22","author":"A Soejima","year":"2004","unstructured":"Soejima A, Matsuzawa N, Hayashi T, Kimura R, Ootsuka T, Fukuoka K, Yamada A, Nagasawa T, Era S. Alteration of redox state of human serum albumin before and after hemodialysis. Blood Purif. 2004;22(6):525\u20139.","journal-title":"Blood Purif"},{"key":"3317_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1744-9987.2010.00841.x","volume":"14","author":"H Terawaki","year":"2010","unstructured":"Terawaki H, Takada Y, Era S, et\u2003al. The redox state of albumin and serious cardiovascular incidence in hemodialysis patients. Ther Apher Dial. 2010;14:465\u201371.","journal-title":"Ther Apher Dial"},{"issue":"Suppl 2","key":"3317_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000496631","volume":"47","author":"T Shigematsu","year":"2019","unstructured":"Shigematsu T, Kuragano T, Kamimura T, Kawada S, Imamura R, Nishian Y, Miyamoto M, Miyamoto T, Nakanishi T. Predilution On-Line hemodiafiltration improves albumin redox in maintenance hemodialysis patients. Blood Purif. 2019;47(Suppl 2):19\u201324.","journal-title":"Blood Purif"},{"issue":"3","key":"3317_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/ckj\/sfab177","volume":"15","author":"M Abe","year":"2021","unstructured":"Abe M, Masakane I, Wada A, Nakai S, Nitta K, Nakamoto H. Super high-flux membrane dialyzers improve mortality in patients on hemodialysis: a 3-year nationwide cohort study. Clin Kidney J. 2021;15(3):473\u201383.","journal-title":"Clin Kidney J"},{"issue":"3","key":"3317_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1681\/ASN.2008060590","volume":"20","author":"F Locatelli","year":"2009","unstructured":"Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R. Membrane permeability outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009;20(3):645\u201354.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"3317_CR24","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1097\/01.ASN.0000096373.13406.94","volume":"14","author":"AK Cheung","year":"2003","unstructured":"Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol. 2003;14(12):3251\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"3317_CR25","first-page":"1","volume":"2","author":"G Donati","year":"2022","unstructured":"Donati G, Gasperoni L, Napoli M, Scrivo A, Zappulo F, Abenavoli C, Hu L, Angelini A, Di Nunzio M, Tringali E, Cingolani A, Marchegiani BC, Rigotti A, La Manna G. Anti-inflammatory Approach in Chronic Dialysis patients with SARS-CoV-2: CTA or PMMA dialyzers? Blood purif. Nov. 2022;2:1\u20138.","journal-title":"Nov"},{"issue":"4","key":"3317_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/hdi.12939","volume":"25","author":"AM Zawada","year":"2021","unstructured":"Zawada AM, Melchior P, Erlenk\u00f6tter A, Delinski D, Stauss-Grabo M, Kennedy JP. Polyvinylpyrrolidone in hemodialysis membranes: impact on platelet loss during hemodialysis. Hemodial Int. 2021;25(4):498\u2013506.","journal-title":"Hemodial Int"},{"issue":"2","key":"3317_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/mps4020026","volume":"4","author":"G Donati","year":"2021","unstructured":"Donati G, Cappuccilli M, Donadei C, Righini M, Scrivo A, Gasperoni L, Zappulo F, La Manna G. Toxin removal and inflammatory state modulation during online hemodiafiltration using two different dialyzers (TRIAD2 study). Methods Protoc. 2021;4(2):26.","journal-title":"Methods Protoc"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03317-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03317-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03317-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T18:09:36Z","timestamp":1700417376000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03317-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3317"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03317-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the local ethics committee of the University of Duisburg-Essen (22-10806-BO). Informed consent was obtained from all the participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants gave written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Karl Oettl has received the Albus Award by Grifols SA, Spain and is consultant of Takeda Pharmaceuticals International AG. Margret Paar has received the Albus Award by Grifols SA, Spain. Andreas Kribben has received grants for clinical studies, speaker\u2019s fees, honoraria, and travel expenses from Actelion, Amgen, Amicus, Alexion, Astellas, Bayer, Baxter, Binding Site, Bristol Myers, Chiesi, CytoSorbents, Fresenius, GlaxoSmithKline, Hexal, Janssen, Kyowa Kirin, MSD, Novartis, Otsuka, Peripal, Pfizer, Roche, Sanofi, Shire, Teva, and Vifor Fresenius Medical. All other authors declare no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}